Epigenetic therapy in urologic cancers: an update on clinical trials

• Autor(a) principal: Faleiro, Inês
• Data de Publicação: 2017
• Outros Autores: Leão, Ricardo, Binnie, Alexandra, de Mello, Ramon Andrade, Maia, Ana-Teresa, Castelo Branco, Pedro
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• DOI: 10.18632/oncotarget.14226
• Texto Completo: http://hdl.handle.net/10316/108295; https://doi.org/10.18632/oncotarget.14226
• topic: clinical trials; epigenetic therapy; urologic cancers; Azacitidine; Clinical Trials as Topic; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3A; Enzyme Inhibitors; Humans; Male; Prostatic Neoplasms

Epigenetic dysregulation is one of many factors that contribute to cancer development and progression. Numerous epigenetic alterations have been identified in urologic cancers including histone modifications, DNA methylation changes, and microRNA expression. Since these changes are reversible, efforts are being made to develop epigenetic drugs that restore the normal epigenetic patterns of cells, and many clinical trials are already underway to test their clinical potential. In this review we analyze multiple clinical trials (n=51) that test the efficacy of these drugs in patients with urologic cancers. The most frequently used epigenetic drugs were histone deacetylase inhibitors followed by antisense oligonucleotides, DNA methyltransferase inhibitors and histone demethylase inhibitors, the last of which are only being tested in prostate cancer. In more than 50% of the clinical trials considered, epigenetic drugs were used as part of combination therapy, which achieved the best results. The epigenetic regulation of some cancers is still matter of research but will undoubtedly open a window to new therapeutic approaches in the era of personalized medicine. The future of therapy for urological malignancies is likely to include multidrug regimens in which epigenetic modifying drugs will play an important role.